GESIDA 3903 team. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: Final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903 (Clinical Infectious Diseases (2008) 47, (1083-1092))

  1. Berenguer, J.
  2. González, J.
  3. Ribera, E.
  4. Domingo, P.
  5. Santos, J.
  6. Miralles, P.
  7. Angels Ribas, M.
  8. Asensi, V.
  9. Gimeno, J.L.
  10. Pérez-Molina, J.A.
  11. Terrón, J.A.
  12. Santamaría, J.M.
  13. Pedrol, E.
Aldizkaria:
Clinical Infectious Diseases

ISSN: 1058-4838

Argitalpen urtea: 2008

Alea: 47

Zenbakia: 12

Orrialdeak: 1611

Mota: Hutsen zuzenketa

DOI: 10.1086/595825 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus